When other mTOR inhibitors, BEX235 or AZD8055, were combined with ABT-263 in vitro, a higher rate of apoptosis was observed, and either one of the mTOR combined inhibitors with navitoclax induced more tumor regression in xenograft models than the drugs alone (93). This evidence concerns the gene MTOR and neoplasm.